awmsg logo



human alpha1-proteinase inhibitor (Respreeza®)


Reference No. 47

Publication date:
22/03/2017


Appraisal information

human alpha1-proteinase inhibitor (Respreeza®) 1000 mg powder and solvent for solution for infusion


Company: CSL Behring UK Ltd
BNF category: Respiratory system
NMG meeting date: 05/10/2016
AWMSG meeting date: 15/02/2017
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 0217
Ministerial ratification: 21/03/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Human alpha1-proteinase inhibitor (Respreeza®) is not recommended for use within NHS Wales for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). The case for clinical effectiveness and cost-effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinician and Patient Involvement Group (CAPIG) Meeting Summary
Download